MedTrace Logo

VISIODOL: Validation of the VISIODOL® Scale

NCT03968991 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2023-03-13

No results posted yet for this study

Summary

The aim of this study is to validate the VISIODOL® scale for screening of pain in people with visual impairment.

Conditions

  • Visual Deficiency
  • Congenital Blindness
  • Acquired Blindness

Interventions

DIAGNOSTIC_TEST

VISIODOL® (Diagnostic tool)

Tool for assessing pain in the blind subject (with congenital or acquired deficiency)

Sponsors & Collaborators

  • University Hospital, Clermont-Ferrand

    lead OTHER

Principal Investigators

  • Gisèle Pickering · University Hospital, Clermont-Ferrand

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-18
Primary Completion
2020-12-28
Completion
2020-12-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03968991 on ClinicalTrials.gov